License and Collaboration Agreement with Regeneron - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended			6 Months Ended
	Oct. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Nov. 30, 2017
License And Collaboration Agreement With Regeneron [Line Items]
Upfront nonrefundable payment										$ 25,000,000.0
Preferred stock, shares issued					0		0		0
Ongoing research plan			$ 300,000				$ 300,000
CDMO Initiation Fee			500,000
Milestone associated payment	$ 1,100,000	$ 4,400,000	500,000				5,500,000
Milestone payment received							5,500,000
Transaction price							46,900,000
Received regeneron agreement amount							25,000,000.0
Preferred stock value issued
Contra-research and development expense					2,200,000	$ 3,800,000	5,200,000	$ 5,700,000
Deferred collaboration liability, current					9,123,000		9,123,000		8,118,000
Deferred collaboration liability, long term					10,204,000		10,204,000		16,431,000
Unbilled accounts receivable due from related party					10,000,000.0		10,000,000.0		$ 11,400,000
Scenario Forecast
License And Collaboration Agreement With Regeneron [Line Items]
Obligation to payment amount				$ 10,000,000.0
Maximum
License And Collaboration Agreement With Regeneron [Line Items]
Third party costs related to investigational new drug			$ 10,500,000		10,000,000.0		10,000,000.0
Series C convertible preferred stock
License And Collaboration Agreement With Regeneron [Line Items]
Preferred stock, shares issued			10,000,000
Series C Preferred Stock
License And Collaboration Agreement With Regeneron [Line Items]
Preferred stock value issued					$ 4,400,000		$ 4,400,000